Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (esophageal apical cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 92 | 0.85 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 12719
Sealed predictions
- CERS3 in dopamine neurons, braak+0.52 (p 0.151) → +0.37 (p 0.321)receipt 12727
Swarm cases
receipt 12727: CERS3 in dopamine neurons, braak
- power
- full sample +0.44 (p 0.066, n 18), 95% CI -0.03 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.48 (p 0.045, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.029, n 18). not the mix.
- skeptic
- leave-one-out range +0.36 to +0.54, sign flips 0; without severely affected donors +0.44 (p 0.066, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CERS3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts